1-2 of 2
Shanthakumar Tyavanagimatt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis

Clinical Trials & Observations
Stephen T. Oh, Ruben A. Mesa, Claire N. Harrison, Prithviraj Bose, Aaron T. Gerds, Vikas Gupta, Bart L. Scott, Jean-Jacques Kiladjian, Alessandro Lucchesi, Tim Kong, Sarah A. Buckley, Shanthakumar Tyavanagimatt, Bryan G. Harder, Karisse Roman-Torres, Jennifer Smith, Adam R. Craig, John Mascarenhas, Srdan Verstovsek
Journal: Blood Advances
Blood Adv (2023) 7 (19): 5835–5842.
https://doi.org/10.1182/bloodadvances.2023010151
Published: 2023
Includes: Supplemental data
Journal Articles

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis

Clinical Trials & Observations
Aaron T. Gerds, Michael R. Savona, Bart L. Scott, Moshe Talpaz, Miklos Egyed, Claire N. Harrison, Abdulraheem Yacoub, Alessandro Vannucchi, Adam J. Mead, Jean-Jacques Kiladjian, Jennifer O’Sullivan, Valentin García-Gutiérrez, Prithviraj Bose, Raajit K. Rampal, Carole B. Miller, Jeanne Palmer, Stephen T. Oh, Sarah A. Buckley, Diane R. Mould, Kaori Ito, Shanthakumar Tyavanagimatt, Jennifer A. Smith, Karisse Roman-Torres, Sri Devineni, Adam R. Craig, John O. Mascarenhas
Journal: Blood Advances
Blood Adv (2020) 4 (22): 5825–5835.
https://doi.org/10.1182/bloodadvances.2020003314
Published: 2020
Includes: Supplemental data